WallStreetZenWallStreetZen

NASDAQ: COLL
Collegium Pharmaceutical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for COLL

Based on 6 analysts offering 12 month price targets for Collegium Pharmaceutical Inc

Min Forecast
$43.00+96.08%
Avg Forecast
$46.83+113.56%
Max Forecast
$50.00+128%

Should I buy or sell COLL stock?

Based on 6 analysts offering ratings for Collegium Pharmaceutical Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although COLL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates COLL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their COLL stock forecasts and price targets.

COLL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-23
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-08-19
lockedlocked$00.00+00.00%2026-08-07
Needham
Top 2%
99
BuyMaintains$46.00+109.76%2026-08-06

1 of 1

Forecast return on equity

Is COLL forecast to generate an efficient return?

Company
77.08%
Industry
52.99%
Market
168.02%
COLL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is COLL forecast to generate an efficient return on assets?

Company
11.26%
Industry
20.47%
COLL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

COLL earnings per share forecast

What is COLL's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$7.51+394.03%
Avg 2 year Forecast
$6.75+343.92%
Avg 3 year Forecast
$6.89+352.96%
COLL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

COLL revenue forecast

What is COLL's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$853.0M+5.54%
Avg 2 year Forecast
$868.0M+7.4%
Avg 3 year Forecast
$880.6M+8.96%
COLL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

COLL earnings growth forecast

How is COLL forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
64.12%
Industry
16.66%
Market
32.52%
COLL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
COLL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
COLL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

COLL revenue growth forecast

How is COLL forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
2.92%
Industry
9.26%
Market
14.54%
COLL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
COLL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

COLL vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
COLL$21.93$46.83+113.56%Buy
IRWD$3.75N/AN/A
AQST$4.62$10.00+116.45%Buy
EVO$1.61N/AN/A
EOLS$7.74$13.00+67.96%Strong Buy
View Top Pharmaceutical Stocks

Collegium Pharmaceutical Stock Forecast FAQ

Is Collegium Pharmaceutical Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: COLL) stock is to Buy COLL stock.

Out of 6 analysts, 2 (33.33%) are recommending COLL as a Strong Buy, 3 (50%) are recommending COLL as a Buy, 1 (16.67%) are recommending COLL as a Hold, 0 (0%) are recommending COLL as a Sell, and 0 (0%) are recommending COLL as a Strong Sell.

If you're new to stock investing, here's how to buy Collegium Pharmaceutical stock.

What is COLL's earnings growth forecast for 2026-2028?

(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual earnings growth rate of 64.12% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 16.66%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.52%.

Collegium Pharmaceutical's earnings in 2026 is $47,915,000.On average, 9 Wall Street analysts forecast COLL's earnings for 2026 to be $244,466,609, with the lowest COLL earnings forecast at $212,164,930, and the highest COLL earnings forecast at $263,895,799. On average, 9 Wall Street analysts forecast COLL's earnings for 2027 to be $219,672,254, with the lowest COLL earnings forecast at $144,208,343, and the highest COLL earnings forecast at $277,227,323.

In 2028, COLL is forecast to generate $224,145,396 in earnings, with the lowest earnings forecast at $150,270,198 and the highest earnings forecast at $293,635,351.

What is COLL's revenue growth forecast for 2026-2028?

(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 2.92% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.54%.

Collegium Pharmaceutical's revenue in 2026 is $808,208,000.On average, 9 Wall Street analysts forecast COLL's revenue for 2026 to be $27,768,635,664, with the lowest COLL revenue forecast at $26,480,735,614, and the highest COLL revenue forecast at $28,898,640,992. On average, 9 Wall Street analysts forecast COLL's revenue for 2027 to be $28,259,248,752, with the lowest COLL revenue forecast at $23,207,268,727, and the highest COLL revenue forecast at $30,970,154,647.

In 2028, COLL is forecast to generate $28,669,775,032 in revenue, with the lowest revenue forecast at $23,736,948,551 and the highest revenue forecast at $32,303,306,999.

What is COLL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: COLL) forecast ROA is 11.26%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 20.47%.

What is COLL's Price Target?

According to 6 Wall Street analysts that have issued a 1 year COLL price target, the average COLL price target is $46.83, with the highest COLL stock price forecast at $50.00 and the lowest COLL stock price forecast at $43.00.

On average, Wall Street analysts predict that Collegium Pharmaceutical's share price could reach $46.83 by Sep 23, 2027. The average Collegium Pharmaceutical stock price prediction forecasts a potential upside of 113.56% from the current COLL share price of $21.93.

What is COLL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: COLL) Collegium Pharmaceutical's current Earnings Per Share (EPS) is $1.52. On average, analysts forecast that COLL's EPS will be $7.51 for 2026, with the lowest EPS forecast at $6.52, and the highest EPS forecast at $8.11. On average, analysts forecast that COLL's EPS will be $6.75 for 2027, with the lowest EPS forecast at $4.43, and the highest EPS forecast at $8.52. In 2028, COLL's EPS is forecast to hit $6.89 (min: $4.62, max: $9.02).

What is COLL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: COLL) forecast ROE is 77.08%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.